ABSTRACT ARP-1 is a ubiquitous orphan nuclear receptor that binds to a site (site A) in the apolipoprotein Al (apoAl) liver-specific enhancer and represses its transcriptional activity In hepatoblastoma HepG2 cells. Electrophoretic mobility shift analysis of HepG2 cell nuclear extracts showed that in addition to ARP-1, site A also binds the orphan nuclear receptors Ear-2 and HNF-4. In in vitro transcription assays, Hela cell nuclear extracts which contain ARP-1 had no effect on transcription from a basal promoter linked to multiple copies of site A. However, supplementation of these extracts with excess amounts of recomblnant ARP-1 resulted In significant stimulation. Supplementation of the extracts with purified polypeptides representing fusions between the ARP-1 N-or C-terminal domains and the yeast activator GAL4 DNA binding domain also stimulated transcription from a basal promoter linked to multiple GAL4 DNA binding sites. Co-immunopreciprtatlon assays using ARP-1-selective antibodies revealed specific physical Interactions between ARP-1 and the basal transcription factor TFIIB. We conclude that ARP-1 possesses Intrinsic transcription activation potential which is modulated, at least In part, by the intracellular balance of other nuclear receptors that also bind to its cognate DNA binding site.
INTRODUCTION
Transcription of mRNA-encoding genes by RNA polymerase n is a complex process subject to regulation at multiple levels (reviewed in 1,2). Basal level transcription is maintained by RNA polymerase II and its associated general transcription factors. Assembly of these factors into a pre-initiation complex on the core promoter elements is thought to be regulated by transcription factors functioning via upstream regulatory sites (3) .
The nuclear hormone receptors comprise an ever expanding superfamily of transcription factors (reviewed in [4] [5] [6] , which includes the receptors for retinoids, vitamin D3, thyroid and steroid hormones and many orphan receptors whose ligands remain unknown (7) . Nuclear hormone receptors feature a double zinc finger DNA binding motif and activate or repress transcription via characteristic cu-acting response elements (4) .
ARP-1 (8), Ear-3/COUP-TF (9,10) and Ear-2 (10) are closely related orphan receptors involved in the regulation of several fundamentally important biological processes, such as neuronal cell fate determination (11) , early embryonic development (12) (13) (14) , modulation of the activity of other nuclear receptors (15, 16) and regulation of genes involved in cholesterol homeostasis (8, (17) (18) (19) . They have been shown to repress transcription of a wide variety of genes in transient transfection assays (8, 12, 13, (17) (18) (19) (20) (21) . Hence these receptors have been accorded a function as general transcriptional repressors. Yet a series of observations suggest that, depending on the organization of the DNA binding site, the promoter architecture and the cell context, ARP-1 and Ear-3/COUP-TF can also function as transcriptional activators (20, (22) (23) (24) . The molecular mechanisms for these discordant observations have not been elucidated, but given the biological significance of these receptors further study is warranted.
ARP-1 was originally identified and cloned (8) as a transcriptional factor that binds to a site (site A) within a powerful liver-specific enhancer (25) located in the 5' flanking region of the human apolipoprotein AI (apoAI) gene (26) . In transient transfection assays, ARP-1 represses the transcriptional activity of the apoAI enhancer in hepatoblastoma HepG2 cells (8) . In addition, ARP-1 overexpression blunts the ability of site A to respond to the 9-cw-retinoic acid receptor RXRa (25, 27) . The recent observation that repression of the apoAI enhancer by ARP-1 can be overcome by several other transcriptional factors that bind to site A or other nearby sites in the apoAI enhancer raised the possibility that ARP-1 repression plays an important role in switching apoAI gene expression between alternative transcription activation pathways (28, 29) .
In this report we used cell-free systems to study the mechanisms by which ARP-1 represses or activates transcription from a basal promoter linked to the apoAI site A. While this approach is commonly employed for a variety of transcription factors, relatively few nuclear hormone receptors (30) (31) (32) have been studied in this way. We first show that HepG2 cell nuclear extracts contain, in addition to ARP-1, substantial amounts of the orphan receptors Ear-2 and HNF-4, which also bind efficiently to the apoAI gene site A. Next, we demonstrate that ARP-1 activates transcription in vitro via at least two activation domains located * To whom correspondence should be addressed N-and C-terminal to the DNA binding domain of ARP-1. Finally, we provide evidence for a physical interaction between ARP-1 and the basal transcription factor TFITB. We conclude that ARP-1 has intrinsic transcription activation potential that is modulated in vivo by cellular co-regulators and the relative abundance of other nuclear receptors that also bind to its cognate DNA binding site.
MATERIALS AND METHODS
Standard molecular biology procedures were employed for all recombinant DNA work (33) .
Bacterial expression of ARP-1 and its derivatives
Two ARP-1 cDNA fragments, one a synthetic double-stranded oligonucleotide which introduces an Ndel restriction site in the first codon of the ARP-1 cDNA (8) and extends up to the Stul site located 5' to the ARP-1 DNA binding domain, the other a StuI-BamHl restriction fragment spanning the DNA binding domain (DBD) derived from the ARP-1 cDNA plasmid pDBP-7 propagated in DM-1 Escherichia coli (GIBCO-BRL) were ligated into the Ndel and BamHl cleaved expression vector 6His-pETlld (34) . The resultant plasmid, pET-ARPAC, was used to express the N-terminal domain of ARP-1 (below) and to generate the full-length ARP-1 expression plasmid (pET-ARP) by insertion of a BamHl fragment encoding the C-terminal portion of ARP-1.
The DNA binding domain (1 -147) of the yeast activator GAL4 (35) was amplified by PCR employing primers which introduced an Ndel site at the N-terminus and BgRl and Ndel restriction sites at the C-terminus. The PCR product was subcloned into the Ndel site of the plasmid pUC19. The ARP-1 BamHl fragment encoding the C-terminal portion of ARP-1 was then subcloned into the Bglll site of the GAL4 DBD PCR product. Finally, the Ndel fragment containing the GAL-ARP fusion was subcloned into the Ndel site of 6His-pETl Id to yield pET-GAL-ARPAN. pET-GAL-X was similarly constructed, except that the ARP-1 BamHl fragment was cloned in the opposite orientation. To generate pET-GAL-ARPAC, the GAL4 DBD PCR product was excised from pUC19 by Ndel digestion and subcloned into the Ndel site of pET-ARPAC.
Plasmids pET-ARP, pET-ARPAC, pET-GAL-ARPAN, pET-GAL-X and pET-GAL-ARPAC were transformed into E.coli BL21(DE3){pLysS} (Novagen) harboring the bacteriophage T7 RNA polymerase. Histidine-tagged ARP-1 and its derivatives were purified over Ni 2+ affinity resin as described (36) . Full-length ARP-1 (but not the deletion derivatives) was found to be proteolytically unstable, accounting for the relatively low yields. An affinity-purified ARP-1 fusion with the maltose binding protein (MBP) (37) was the gift of Drs C. Palmer and E. Johnson (Scripps Research Institute, La Jolla, CA).
Generation of anti-ARP-1 antibody
Antibodies against affinity-purified ARPAC were raised using standard methods (Pocono Rabbit Farm and Labs). Briefly, the protein was initially injected into rabbits (150 ng/rabbit) with complete Freund's adjuvant. Booster injections (100 \ig protein/ rabbit in incomplete Freund's adjuvant) were given 2 and 4 weeks after the first injection. Subsequent boosting was at 4 week intervals for 4 months. Rabbits were bled 2 weeks after each injection. Serum was collected and titered for reactivity to recombinant ARP-1 by Western blotting.
Templates for in vitro transcription
All templates for in vitro transcription contained a G-less cassette, allowing easy detection of discrete transcripts synthesized in the absence of GTP (38) . Plasmid pG5HIV.ML, which contains five copies of the GAL4 binding site upstream of a synthetic core promoter derived from the HTV and Ad2 ML promoters, was a gift of Drs R. Bernstein and M. Meisterernst (39) . Each of these plasmids contains an -400 bp G-less cassette. Plasmid pML200 containing the wild-type Ad2 ML promoter upstream of a 200 bp G-less cassette was obtained from Dr U. Schibler (40) .
Plasmid pA4 X MLA53, containing four copies of site A of the apoAI liver-specific enhancer (25) upstream of the adenovirus major late (ML) core promoter (41), was constructed as follows. First, the Smal site of plasmid pMLA53 (41) was modified to a BgM site. Subsequently, phosphorylated and multimerized site A oligonucleotide with GATC overhangs was ligated into it. After nucleotide sequencing, a construct containing four copies of site A was selected for further analysis. Plasmids were purified over Qiagen columns and then extracted with phenol and chloroform prior to transcription.
In vitro transcription
Reactions of 25 ^1 contained 25 mM HEPES, pH 7.9, 11 mM MgCl2,0.1 mM EDTA, 0.1 mM o-methylguanosine (Pharmacia), 2 U RNase Tl (Boehringer), 20 U RNasin (Promega), 500 mM each of ATP and CTP (Pharmacia), 25 \xM [a- 32 P]UTP at 800 Ci/mmol, 5 mM dithiothreitol, 75 fj.g HeLa nuclear extract proteins prepared by the method of Dignam et al. (42) . The amount of G-less template varied and is specified in the figure legends. Incubation conditions were variable and are specified. Reactions were terminated by addition of 10 mM EDTA, 0.5% SDS, 40 u.g yeast tRNA, 0.3 M sodium acetate, pH 5.2. Following extraction with phenol, the RNA was precipitated by ethanol, collected by centrifugation, washed with ethanol, dried and re-suspended in sample buffer containing 80% formamide and Bromophenol blue in 10 mM Tris-HCl, pH 7.4. Electrophoresis was in 5% polyacrylamide gels containing 7 M urea in Tris-borate buffer. Gels were prepared for autoradiography as usual. When indicated, autoradiograms were scanned and band intensities quantitated in a Molecular Dynamics Laser Densitometric Scanner. the beads were re-suspended in 20 uJ Laemmli sample buffer and analyzed by SDS-PAGE, followed by autoradiography.
Co-immunoprecipitations

RESULTS
Ligand-independent binding of recombinant ARP-1 to site A
For functional studies and for generation of an anti-ARP-1 antiserum we employed a bacterial expression system to overproduce ARP-1. ARP-1 cDNA (8) was subcloned into a bacterial expression vector (Materials and Methods) and the expressed protein was purified by affinity chromatography. The recombinant ARP-1 preparation was visualized as a -51 kDa polypeptide (Fig. 1A) . The slower mobility of the bacterially expressed ARP-1 relative to the natural protein (47 kDa) (8) is attributable to the presence of 20 additional amino acids (including six histidine residues) added to the N-terminus for facilitated purification (34) . As evidenced by the build up of low molecular weight ARP-1-derived species, the recombinant ARP-1 preparation (rARP-1) was not proteolytically stable. In contrast, a truncated derivative of ARP-1 in which the C-terminal domain has been deleted (ARPAQ was more stable when expressed and purified using the same bacterial system (lane 3). Purified ARP AC was used to generate an anti-ARP-1 antiserum in rabbits (see below and Materials and Methods).
We first asked if affinity-purified ARP-1 displayed any ligand and/or an auxiliary factor dependence (45) for DNA binding. The electrophoretic mobility shift assay (EMSA) in Figure IB shows that bacterially expressed ARP-1 bound efficiently to site A, revealing two predominant bands designated Cl and C2. Consistent with the presence of the affinity tag (see above) in bacterially expressed ARP-1, complex Cl was somewhat slower migrating relative to the solitary complex yielded by ARP-1 that has been produced in vitro in a rabbit reticulocyte lysate (compare lanes 1 and 2). Complex C2 appeared to be peculiar to the bacterial preparation and can likely be attributed to a proteolytic fragment of ARP-1 (see Fig. IB, lane 1) . Furthermore, binding of recombinant ARP-1 to site A was specific, since it could be competed for by excess site A, but not by excess double-stranded oligonucleotides with irrelevant sequences (not shown).
These results unequivocally indicate that the DNA binding ability of bactenally expressed ARP-1 does not require a ligand or auxiliary factors.
ARP-1 is an abundant nuclear protein which constitutes part of the apoAI site A complex
To determine the epitopes on ARP-1 recognized by the antibody we tested it for its ability to supershift DNA complexes formed by various derivatives of ARP-1 on a site A probe in EMS A. The following polypeptides were expressed in vitro in rabbit reticulocyte lysates: (i) full-length ARP-1; (ii) ARP NH 2 -DBD, which contains the ARP-1 N-termrnal domain and the putative DNA binding domain; (in) ARP DBD-C, which contains the DNA binding domain and the entire C-terminal segment of ARP-1; (i v) ARP DBD, which contains only the DNA binding domain.
As expected, the anti-ARP-1 antibody efficiently supershifted the DNA complexes formed by full-length ARP-1 ( Fig. 2 A, lanes  2 and 7) . Similar quantitative supershifting was also observed with the ARP NH 2 -DBD-DNA complex (lanes 3 and 8). In contrast, the DNA complexes formed by the polypeptides ARP DBD-C and ARP DBD, which lack the ARP-1 N-terminal segment, failed to respond effectively to the antibody. These results confirmed the preference of this antibody for the ARP-1 N-terrrunal half.
Considering the high degree of sequence conservation in the C-terminal half, but not the N-terminus, in ARP-1, Ear3/COUP-TF and Ear-2, we examined the ability of the ARP-1 antibody to discriminate between DNA complexes formed by each of these proteins. As evidenced by the data of Figure 2B , the antibody could indeed distinguish between ARP-1-and Ear-2-DNA complexes, since while the ARP-1-DNA complex is efficiently supershifted, that of Ear-2 is not. These results are concordant with the pronounced amino acid sequence divergence in the N-termiru of the two proteins (8, 10) . In addition, although the Ear-3/COUP-TF complex is also supershifted by the ARP-1 antibody, the migration of this complex is significantly faster than the analogous complex with ARP-1 (Fig. 2, compare lanes 4 and  6) . This suggests that the antibody can discriminate between Ear-3/COUP-TF and ARP-1 in EMS A. Similar results have also been obtained with Ear-3/COUP-TF or ARP-1 transiently expressed in Cos-1 cells (X. P. Lu, personal communication) DNA complexes formed by RXRcx, which does not share extensive sequence homology with ARP-1, are unaffected by the ARP-1 antibody (data not shown).
To evaluate the presence of ARP-1 in liver and non-liver cells, Western blot analysis of nuclear extracts from HeLa cells and rat liver was performed (Fig. 3A) . In this experiment the anti-ARP-1 repreGiven the high levels of ARP-1 in nuclear extracts and previous sents a cross-reactive species, perhaps identical to that reported structural and functional studies (8, 28, 29) , which strongly earlier to cross-react with an Ear-3/COUP-TF antiserum (46) . A. Therefore we employed the anti-ARP antiserum to supershift the DNA complexes formed by nuclear extract proteins on this site. As evidenced by the pronounced supershifted complexes, ARP-1 from HepG2 extracts bound to site A (Fig 3B, lane 3) . However, despite the relatively large amount of antibody used in this experiment, the supershifting was not complete, hinting at the existence of multiple populations consisting of additional nuclear receptors not recognized by the antibody. Indeed, the complex was additionally found to respond to antibodies against the orphan nuclear receptors HNF^4 and Ear-2 (lanes 4 and 5).
Various combinations of antisera were also employed to ascertain if the original complex could be accounted for by these factors (Fig. 3C) . Quantitative supershifting could only be observed when antibodies against ARP-1, HNF^l and Ear-2 were included in the binding reaction (lane 5). Similar results have been obtained with nuclear extracts from non-liver-derived cells (data not shown). We therefore conclude that the retardation complex observed with site A reflects an aggregate of complexes containing ARP-1 (and/or Ear-3/COUP-TF), HNF^ and Ear-2.
Activation of transcription by ARP-1 in vitro
Next we examined the effect of native ARP-1 in nuclear extracts on transcription in vitro. For this purpose we employed a template containing a G-free cassette reporter (38) in which basal transcription through adenovirus ML core promoter elements (41) was subjected to influences mediated by multimenzed site A (A4 X MLA53) (see Materials and Methods). Control templates contained either the core promoter alone (MLA53) or the core promoter with its natural upstream activating sequences (ML) containing binding sites for the transcription factor USF/MLTF, previously shown to be present in HeLa nuclear extracts (41). Upon transcription of these templates by HeLa nuclear extracts in vitro a distinct effect of USF on transcription levels is immediately apparent (Fig. 4A ) from the relatively elevated levels of transcription displayed by the template containing the USF binding site ML. This reflects the intrinsic ability of the system to support activated transcription. In contrast, no change is apparent in the transcription levels of templates MLA53 and A4 X MLA53 (lanes 2 and 3) . These results are indicative of the inability of endogenous ARP-1 present in HeLa nuclear extracts to affect basal transcription activity of the ML core promoter.
Given that supershifting of the complex yielded by HeLa nuclear extract (Fig. 3B and data not shown) is incomplete, despite the excess amounts of antibody added, these results strongly suggest that other factors (nuclear receptors), not immunocrossreactive with anti-ARP-1 antibody, could bind to site A and interfere with the activity of endogenous ARP-1. Thus the lack of effect on in vitro transcription from templates containing multiple copies of site A upstream of core promoter elements could be the outcome of the net effect of positive and negative factors functioning through site A. Alternatively, endogenous HeLa ARP-1 is in an inactive form, e.g as a result of covalent modification or if it exists in association with a neutralizing heterodimeric partner.
Therefore excess recombinant ARP-1 was first pre-incubated with A4 X MLA53, as well as a control template Ad2 ML200 that lacks site A, and transcription was initiated by addition of HeLa nuclear extract (Fig. 4B and C) . Two preparations of recombinant ARP-1 were employed for this analysis as follows: (I) histidinetagged ARP-1; (ii) in view of its greater proteolytic stability, a derivative of ARP-1 in which the receptor is present as a fusion with the maltose binding protein (MBP) (37) . Both preparations of ARP-1 stimulated transcription from the A4 X MLA53 template, but not from Ad2 ML200, the template lacking site A. The activation response was optimized by varying the reaction conditions (salt, temperature, template concentration; data not shown). Under the conditions shown, transcnptional enhancement was consistently (averaging 2.7 ± 0.4-fold over five measurements) observed with recombinant histidine-tagged ARP-1 (Fig. 4B) . In titration experiments with the MBP-ARP-1 fusion protein transcnptional enhancement exceeded 4-fold (Fig,  4C ). An equivalent amount of a control preparation from E.coli not expressing ARP-1 (Fig. 1A, lane 1 ) had no effect (data not shown). These results indicate that under these conditions ARP-1 functions as a transcriptional activator in vitro.
Multiple transcription activation domains in ARP-1
Next we examined whether the ability of ARP-1 and its derivatives to activate transcription was transferable to a heterologous DNA binding domain. For this purpose we fused derivatives of ARP-1 to the DNA binding domain of the yeast transcription activator GAM (GAL4 DBD; see Materials and Methods). In this way various portions of ARP-1 could be delivered to a test template containing GAL4 binding sites upstream of a core promoter (35, 39) . This approach has the advantage that it delivers ARP-1 to the core promoter elements independently of site A, thus eliminating possible interference from other factors that also bind to site A. Additionally, the domains in ARP-1 responsible for this effect could be identified. The following constructs were made (see Materials and Methods): (i) GAL4 DBD fused to an unrelated polypeptide sequence (GAL-X), (ii) GAL4 DBD fused to the N-terminal half of ARP-1 (GAL4-ARPAC); (iii) GAL4 DBD fused to the C-terminal half of ARP-1 (GAL4-ARPAN). The fusion products were expressed as histidine-tagged proteins in E.coli and purified by affinity chromatography. SDS-PAGE analysis of these fusion proteins showed that they are proteolytically stable (data not shown). The activity of these peptides was then examined in an in vitro transcnption system containing the test template G5HI V.ML, which possesses five GAL4 binding sites upstream of a synthetic core promoter (39), together with the control template Ad2 ML200 (Fig. 5) . Under the conditions employed, the template G5HTV.ML, which displays little basal activity on its own, was weakly responsive to the fusion protein GAL-X, possibly reflecting the intrinsic activation domain of the GAL4 DBD (47) . The presence of GAL4-ARPAC enhanced transcription from GAL4 templates more than 5-fold over that observed with GAL-X. Similarly, GAL4-ARPAN activated transcription from GAL4 templates 3.5-fold over that observed with GAL-X. The response was dependent upon the GAL4 DNA binding site on the test template, since neither the control template Ad2 ML200 nor a template (HTV.ML), containing the synthetic core promoter elements of the test template but not the GAL4 DNA binding sites (not shown), responded to these polypeptides.
We therefore conclude that ARP-1 possesses at least two activation domains, one in each of the N-and C-terminal halves of the protein.
Direct interaction of ARP-1 with the basal transcription factor TTUB
Activation of transcnption by factors bound to their upstream binding sites is thought to be the outcome of facilitated recruitment of basal transcription factors functioning through core promoter elements. TBP, the DNA binding component of TFIID (48) and TFTTB (49) have thus been identified as targets of a variety of activators. In an attempt to decipher the mechanism whereby ARP-1 mediates transcription activation in vitro, we tested whether it physically interacted with TFUB. Physical interactions between ThllB and other nuclear receptors have previously been observed (30, 51, 52) . The anti-ARP-1 antibody was therefore used to determine whether TFUB could be co-immunoprecipitated with recombinant ARP-1. Figure 6 shows that a substantial amount of input THIB could be Control experiments confirmed that the interaction is specific, since pre-immune serum did not precipitate TFUB either with bacterial proteins or with ARP-1 and ARPAC (lane 2-4). In addition, radiolabeled luciferase was not preferentially precipitated by ARP-1 antibodies in the presence of ARP-1 (data not shown). These results indicate that ARP-1 can contact TFUB through its N-terminal half. The N-terminal region of ARP-1 is rather rich in glutamine and proline residues (8, 17) , as is characteristic of some classes of transcription activators (3, 52) . Our results, therefore, correlate well with the demonstration that a proline-rich activator can target THIB (53) . The potential interactions of the C-terminal region with TFTIB have not been evaluated; also, no obvious activation motif is discernible in the C-terminal region.
These results strongly argue for an activation mechanism whereby ARP-1 directly targets components of the basal transcription machinery, specifically TFUB.
DISCUSSION
ARP-1 as an activator of transcription
Although ARP-1 has been consistently found to repress transcription in in vivo transfection experiments employing site A-dependent reporters (8, 28, 29) , our in vitro transcription data clearly show that it also possesses intnnsic activation potential. This duality in ARP-1 function is thus similar to what has been described for several other transcription factors (54) (55) (56) (57) .
That the activation potential of ARP-1 is revealed in cell-free transcription systems, which most likely lack any small dialyzable potential ligands, suggests that functional activity of this orphan receptor is ligand-independent. It is of course possible that ARP-1-mediated repression requires an intracellular ligand or cofactor. If so, the situation would be reminiscent of the thyroid hormone receptor, which displays the converse characteristics: it acts as a constitutive silencer in the absence of the appropriate hormone but activates transcription in its presence (30, 58) Perhaps a more intriguing possibility is that our in vitro transcription system lacks a 'co-repressor' which mediates ARP-1 repression in vivo (59) . Our current data suggest that in vitro ARP-1-mediated activation results from direct interactions of the ARP-1 activation domains with components of the basal transcription machinery. Furthermore, given the rough correspondence of the activation domains with the previously mapped repression domains (29) , it is conceivable that in vivo a putative co-repressor(s) masks the ARP-1 activation domains, thus inhibiting its intrinsic transactivation potential.
An alternative, but not mutually exclusive, possibility is that both the repression and activation effects of ARP-1 are mediated via direct physical interactions with TF11B. We have previously suggested that THIB can exist in a productive as well as a non-productive conformation (36) . Indeed, an activator-induced conformation of TFIIB has recently been described (60) . Hence, depending on the configuration of ARP-1, which is in turn governed by parameters such as a putative ligand, cofactor or promoter context (see below), either of the two THIB conformations might be induced, leading to activation (productive conformation) or repression (non-productive conformation).
The activation potential of ARP-1 can also be uncovered in selected in vivo situations. Thus, in co-transfection assays ARP-1 activates the SV40 early promoter (S. K. Karathanasis, unpublished results). Similar observations have been made with Ear-3/COUP-TF (20) . Ear-3/COUP-TF activates transcription from a COUP binding site of the ornithine transcarbamylase gene in the context of the thymidine kinase promoter (20) Similarly, a chimeric Ear-3/COUP-TF whose DNA binding domain was replaced with that of the progesterone receptor activated transcription via a progesterone receptor binding element in response to dopamine treatment of the transfected cells (61) . ARP-1 has also been implicated as a transcriptional activator of the genes encoding intestinal fatty acid binding protein (22) , arrestin (23) and neurotensin (M. B. Evers, personal communication). Finally, Ear-3/COUP-TF functions as a positive auxiliary factor for glucocorticoid induction of phosphoenolpyruvate carboxykinase gene transcription (24) . These findings and the data in the current report argue that, depending upon the promoter and cell contexts, ARP-1 and Ear-3/COUP-TF can function either as activators or repressors This, taken together with the ability of these factors to displace factors previously bound to the same site (see, for example, 17) further extends the regulatory potential of this class of nuclear receptors.
Role of ARP-1 in apoAI transcription
Our demonstration that ARP-1 and/or Ear-3/COUP-TF in HepG2 nuclear extracts can occupy site A complement earlier results which argued for a regulatory role for these nuclear receptors in apoAI gene transcription (8, 28, 29) . We have previously suggested that the multiprotein complex assembled at the apoAI liver-specific enhancer is in a state of continual flux in response to external stimuli that influence apoAI gene expression (29, 62) . In this study we were able to immunologically detect several subpopulations of the site A complex (Fig. 3) containing the orphan receptors HNF4 and Ear-2, in addition to ARP-1 and/or Ear-3/COUP-TF. These results are consistent with the demonstration by us (25, S Malik, unpublished results) and others (63) that these factors can influence apoAI gene expression. Whether and under what circumstances the intrinsic activation potential of ARP-1 revealed in this study influences the activity of the apoAI enhancer is currently under investigation. Finally, as we noted previously (20, 29) , the impact of ARP-1 on the activity of the apoAI enhancer is subject to modulation by other nuclear receptors that also bind to site A, possibly by means of competition for binding to the site or by formation of inactive heterodimers with ARP-1 (43) . Although this situation formally resembles that of the cAMP response element, where fine tuning of the response is modulated by the relative abundance of both activators and repressors binding to the element (64) , the ability of ARP-1 to function as either an activator or repressor blurs the simple concept of repressors and activators in fine tuning gene expression. Future studies will be aimed toward identification of physiological stimuli that switch ARP-1 from its repressor to activator modes in vivo and the roles of the cell and promoter contexts in assimilation of these ARP-1 transcnptional signals.
